Skip to main content

Table 1 Patient demographics and core baseline disease characteristics by treatment (pooled safety analysis set)

From: Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease

  CAD106 (2201) CAD106 (2202) CAD106 (total) Placebo (total)
  N = 22 N = 25 N = 47 N = 11
Sex, n (%)     
 Male 14 (63.6) 15 (60.0) 29 (61.7) 6 (54.5)
 Female 8 (36.4) 10 (40.0) 18 (38.3) 5 (45.5)
Age (yr)     
 Mean (SD) 65.6 (7.1) 70.5 (8.7) 68.2 (8.2) 66.3 (6.9)
Age group, n (%)     
 <65 yr 10 (45.5) 6 (24.0) 16 (34.0) 6 (54.5)
 65–75 yr 10 (45.5) 9 (36.0) 19 (40.4) 4 (36.4)
 >75 yr 2 (9.1) 10 (40.0) 12 (25.5) 1 (9.1)
Race, n (%)     
 Caucasian 22 (100.0) 24 (96.0) 46 (97.9) 10 (90.9)
 Black 0 (0.0) 1 (4.0) 1 (2.1) 0 (0.0)
 Other 0 (0.0) 0 (0.0) 0 (0.0) 1 (9.1)
Years of education     
 Mean (SD) 11.7 (2.7) 14.2 (3.2) 13.1 (3.2) 12.2 (4.1)
MMSE score at baseline     
 Mean (SD) 23.1 (2.2) 21.9 (1.9) 22.5 (2.1) 22.8 (2.3)
Time since first symptom of AD was noticed by patient/caregiver (yr)    
 Mean (SD) 5.4 (2.7) 3.3 (2.2) 4.3 (2.6) 4.5 (1.8)
Time since first symptom of AD was first diagnosed by physician (yr)    
 Mean (SD) 2.0 (1.7) 1.3 (1.3) 1.6 (1.5) 1.8 (1.3)
ApoE4 carrier status, n (%)*     
 Missing 2 (9.1) 2 (8.0) 4 (8.5) 1 (9.1)
 Non-ApoE4 9 (40.9) 3 (12.0) 12 (25.5) 1 (9.1)
 One ApoE4 8 (36.4) 15 (60.0) 23 (48.9) 5 (45.5)
 Two ApoE4 3 (13.6) 5 (20.0) 8 (17.0) 4 (36.4)
  1. AD, Alzheimer’s disease; ApoE4, Apolipoprotein E4 allele; MMSE, Mini Mental State Examination; N, Number of subjects in treatment group; n, Number of patients with a measurement; SD, Standard deviation. *Percentage based on the number of patients genotyped.